Latuda, an antipsychotic medication, has not yet seen a generic version available in 2023 or 2024. The brand-name drug, manufactured by Sunovion Pharmaceuticals, is used to treat schizophrenia and bipolar depression [1].
When will generic Latuda be available?
The exact release date for generic Latuda is contingent on patent expirations and any potential legal challenges to those patents. Information on patent status can be found at DrugPatentWatch.com [2].
What are the patents protecting Latuda?
Latuda is protected by several patents. The primary patent for the active ingredient, lurasidone hydrochloride, is set to expire in 2027. However, additional patents covering methods of use and formulations could extend market exclusivity beyond this date [2].
Are there any ongoing legal disputes regarding Latuda patents?
Patent litigation is common for branded drugs approaching their exclusivity end dates. Companies often challenge existing patents to pave the way for generic competition. Details of any ongoing legal actions related to Latuda's patents are publicly available through patent databases and legal filings [2].
How does generic Latuda's availability impact pricing?
Once generic versions of Latuda become available, the price of the medication is expected to decrease significantly. This is a typical market dynamic where generic competition drives down costs for consumers and insurance providers [2].
What is lurasidone hydrochloride?
Lurasidone hydrochloride is the active pharmaceutical ingredient in Latuda. It is an atypical antipsychotic that works by affecting the activity of certain neurotransmitters in the brain [1].